Samsung Epis Holdings Launches Epis NexLab to Advance Next-Generation Biotechnology

Epis NexLab will concentrate on transforming scalable core technologies into platforms for discovering diverse new drug candidates.

Samsung Epis Holdings Co., Ltd. has announced the formation of a new subsidiary, Epis NexLab Co., Ltd., aimed at developing next-generation biotechnology platforms.

Epis NexLab will concentrate on transforming scalable core technologies into platforms for discovering diverse new drug candidates. These may be developed in-house or in partnership with global pharmaceutical companies.

The company plans to explore new modalities, including amino acid or peptide conjugate platform technologies.

Peter Seongwon Hong, who will serve as CEO of Epis NexLab in addition to his role as executive vice president and head of research and early development at Samsung Bioepis, will also join the board of Samsung Epis Holdings as a non-executive director.

“Building on the R&D expertise accumulated through years of developing quality-assured biologics at Samsung Bioepis, we will focus on securing next-generation biotechnology platforms that can drive sustainable growth for the new company beyond the biosimilar business,” Hong said. “Our long-term goal is to become a leading biotechnology company in next-generation therapeutic technologies, and we will be relentless in our efforts to drive this growth through innovative research and development and strategic investment.”

Established in 2025 as a wholly owned subsidiary of Samsung Epis Holdings, Epis NexLab aims to advance development platforms by transforming peptide-related technologies. The focus will be on discovering innovative treatment modalities to develop multiple therapeutic candidates targeting a broad range of diseases.

Stay tuned for more such updates on Digital Health News